Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation
The present invention relates to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a stable liquid antibody formulation and its pharmaceutical preparation and use. This invention is exemplified by an aqueous formulation of an anti-vascular endothelial growth factor (VEGF) antibody.
1. An aqueous formulation comprising:
about 25 mg/ml of an anti-vascular endothelial growth factor (VEGF) antibody;
about 20 mM histidine or succinate buffer;
about 85 mg/mL sucrose;
about 0.2 mg/ml polysorbate 80;
about 0.05 mg/ml EDTA;
wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8; and
wherein the formulation has pH at about 5.5 or 5.8.
2. The aqueous formulation of claim 1 , wherein the formulation comprises histidine buffer.
3. The aqueous formulation of claim 1 , wherein the formulation comprises succinate buffer.
4. The aqueous formulation of claim 1 , wherein the formulation has pH at about 5.5.
5. The aqueous formulation of claim 1 , wherein the formulation has pH at about 5.8.